

Cristina Suárez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2635069/publications.pdf>

Version: 2024-02-01

73
papers

5,547
citations

172386

29
h-index

91828

69
g-index

77
all docs

77
docs citations

77
times ranked

6299
citing authors

#	ARTICLE	IF	CITATIONS
1	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	3.2	32
2	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 292-303.	5.1	42
3	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	3.4	75
4	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. <i>European Urology</i> , 2022, 82, 212-222.	0.9	56
5	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e2216379.	2.8	10
6	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898.	5.1	114
7	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	0.9	76
8	Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. <i>European Radiology</i> , 2021, 31, 1460-1470.	2.3	87
9	The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 339-339.	0.8	6
10	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	13.9	961
11	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	0.8	145
12	Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. <i>Current Opinion in Urology</i> , 2021, 31, 242-248.	0.9	4
13	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	3.6	54
14	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
15	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	2.6	18
16	PARP inhibitors in advanced prostate cancer: when to use them?. <i>Endocrine-Related Cancer</i> , 2021, 28, T79-T93.	1.6	5
17	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	0.8	69
18	ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2021, 32, 1511-1519.	0.6	113

#	ARTICLE	IF	CITATIONS
19	A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. <i>Oncology Research and Treatment</i> , 2021, 44, 547-556.	0.8	11
20	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, , .	0.9	9
21	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 594023.	1.3	7
22	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	5.1	324
23	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. <i>Cancer Treatment Reviews</i> , 2020, 86, 102000.	3.4	19
24	Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. <i>Investigational New Drugs</i> , 2020, 38, 1570-1579.	1.2	70
25	SEOM clinical guideline for treatment of kidney cancer (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 256-269.	1.2	18
26	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
27	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
28	Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits. <i>EMBO Molecular Medicine</i> , 2020, 12, e11889.	3.3	4
29	Latest progress in molecular biology and treatment in genitourinary tumours. <i>Clinical and Translational Oncology</i> , 2020, 22, 2175-2195.	1.2	2
30	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019, 25, 1706-1714.	15.2	407
31	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	6.3	778
32	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. <i>Medical Oncology</i> , 2019, 36, 29.	1.2	0
33	Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 344-352.	0.4	5
34	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4569-4569.	0.8	23
35	A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 545-545.	0.8	40
36	Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 550-550.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Nanoparticles as theranostic vehicles in prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S29-S29.	0.7	1
38	Prognostic and Predictive Factors for Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 309-331.	1.7	5
39	SEOM clinical guideline for treatment of kidney cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 47-56.	1.2	15
40	Detection of circulating tumor DNA for advanced bladder cancer: where are we going?. <i>Translational Andrology and Urology</i> , 2018, 7, S101-S103.	0.6	1
41	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
42	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
43	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4506-4506.	0.8	69
44	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	0.8	12
45	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	0.8	164
46	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
47	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. <i>Scientific Reports</i> , 2017, 7, 41371.	1.6	3
48	Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. <i>Targeted Oncology</i> , 2017, 12, 277-288.	1.7	39
49	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 171-190.	2.0	22
50	A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4598-TPS4598.	0.8	23
51	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 431-431.	0.8	59
52	Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 30410-30421.	0.8	19
53	Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2016, 21, 535-536i.	1.9	54
54	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. <i>Cell Reports</i> , 2016, 15, 1134-1143.	2.9	96

#	ARTICLE	IF	CITATIONS
55	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. <i>Cancer Treatment Reviews</i> , 2016, 50, 208-216.	3.4	19
56	Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. <i>Targeted Oncology</i> , 2016, 11, 129-141.	1.7	3
57	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4557-4557.	0.8	4
58	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 551-551.	0.8	2
59	Integrated analysis of mRNA and miRNA to unravel novel mechanisms of sunitinib long term response in mRCC.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16080-e16080.	0.8	0
60	New advances in genitourinary cancer: evidence gathered in 2014. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 443-464.	2.7	4
61	Renal cell carcinoma avatar mouse models for the personalized cancer therapy era.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15627-e15627.	0.8	0
62	Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma. <i>Oncologist</i> , 2014, 19, 917-918.	1.9	4
63	Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> : A Multicenter Clinical Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1105-1112.	2.9	67
64	A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4520-4520.	0.8	7
65	Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2039-2039.	0.8	2
66	C-MYC, HER2, and HER3 expression in localized prostate cancer (PC) treated with radical radiotherapy: Modulation by statins use and correlation with time to progression.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16045-e16045.	0.8	0
67	Phase II clinical and pharmacokinetic (PK) trial of zalypsis (Z) in patients with urothelial carcinoma (UC) progressing after a first-line platinum-based regimen.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15001-e15001.	0.8	0
68	An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4679-TPS4679.	0.8	0
69	Senescence, a new concept in pathologic response evaluation of rectal carcinomas (RC) after neoadjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21021-e21021.	0.8	0
70	Molecular basis for the treatment of renal cell carcinoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 15-21.	1.2	17
71	Influence of carbapenem resistance on mortality and the dynamics of mortality in <i>Pseudomonas aeruginosa</i> bloodstream infection. <i>International Journal of Infectious Diseases</i> , 2010, 14, e73-e78.	1.5	48
72	Clinical impact of imipenem-resistant <i>Pseudomonas aeruginosa</i> bloodstream infections. <i>Journal of Infection</i> , 2009, 58, 285-290.	1.7	29

#	ARTICLE	IF	CITATIONS
73	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. Clinical Drug Investigation, 0, , .	1.1	0